Najafian Aida, Alyasin Ashraf, Aghahosseini Marziyeh, Hosseinimousa Sedigheh, Kazemi Seyyedeh Neda
Department of Infertility, Shariati Hospital, Tehran University of Medical Science, Tehran, Iran.
Department of Obstetrics and Gynecology and Female Infertility Unit, Tehran University of Medical Sciences, Tehran, Iran.
Clin Exp Reprod Med. 2023 Dec;50(4):285-291. doi: 10.5653/cerm.2023.06086. Epub 2023 Oct 24.
Infertility can result from a diminished ovarian reserve, but a potential remedy exists in the form of platelet-rich plasma (PRP) administration. This treatment involves both biological factors and tissue trauma mechanisms, which stimulate folliculogenesis, making it a promising and effective strategy. We assessed the impact of direct PRP injections into the ovaries on the fertility outcomes of women classified as poor responders.
A quasi-experimental study was conducted from April 2021 to December 2022, focusing on patients classified as POSEIDON grade 3 or 4. PRP injections were administered into both ovaries. After 3 months, data were collected on anti-Müllerian hormone (AMH) level, follicle-stimulating hormone (FSH) level, and the numbers of oocytes, mature oocytes, and good-quality embryos following ovarian stimulation. We then compared the data from before and after PRP injection.
This study included 50 women, with a mean of 39 years (interquartile range [IQR], 35 to 43) and 4 years (IQR, 2 to 6) for age and infertility duration, respectively. FSH levels decreased after treatment, while AMH levels and the numbers of oocytes, metaphase II oocytes, and high-quality embryos increased. However, only the increase in high-quality embryos was significant. The pregnancy and spontaneous pregnancy rates were 20% and 14%, respectively. Notably, women with secondary infertility exhibited a significantly higher pregnancy rate than those with primary infertility.
Ample evidence suggests that PRP can enhance ovarian function. However, further studies are needed to identify the appropriate candidates for this procedure, establish the optimal PRP preparation method, and standardize the procedure for its adjuvant use in assisted reproductive technology cycles.
卵巢储备功能下降可导致不孕,但富含血小板血浆(PRP)注射是一种潜在的治疗方法。这种治疗涉及生物因素和组织创伤机制,可刺激卵泡生成,是一种有前景且有效的策略。我们评估了直接向卵巢注射PRP对被归类为低反应者的女性生育结局的影响。
2021年4月至2022年12月进行了一项准实验研究,重点关注被归类为波塞冬3级或4级的患者。将PRP注射到双侧卵巢。3个月后,收集卵巢刺激后抗苗勒管激素(AMH)水平、促卵泡生成素(FSH)水平以及卵母细胞、成熟卵母细胞和优质胚胎数量的数据。然后比较PRP注射前后的数据。
本研究纳入50名女性,年龄和不孕时间的平均值分别为39岁(四分位间距[IQR],35至43岁)和4年(IQR,2至6年)。治疗后FSH水平下降,而AMH水平以及卵母细胞、中期II卵母细胞和优质胚胎数量增加。然而,只有优质胚胎数量的增加具有显著性。妊娠率和自然妊娠率分别为20%和14%。值得注意的是,继发性不孕女性的妊娠率显著高于原发性不孕女性。
充分证据表明PRP可增强卵巢功能。然而,需要进一步研究以确定该手术的合适人选,建立最佳的PRP制备方法,并规范其在辅助生殖技术周期中辅助使用的程序。